Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Accumulated Depreciation (2016 - 2024)

Historic Accumulated Depreciation for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $27.5 million.

  • Ocular Therapeutix's Accumulated Depreciation rose 1645.23% to $27.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $27.5 million, marking a year-over-year increase of 1645.23%. This contributed to the annual value of $27.5 million for FY2025, which is 1645.23% up from last year.
  • Per Ocular Therapeutix's latest filing, its Accumulated Depreciation stood at $27.5 million for Q4 2025, which was up 1645.23% from $23.6 million recorded in Q4 2024.
  • Ocular Therapeutix's 5-year Accumulated Depreciation high stood at $27.5 million for Q4 2025, and its period low was $15.2 million during Q4 2021.
  • In the last 5 years, Ocular Therapeutix's Accumulated Depreciation had a median value of $20.3 million in 2023 and averaged $20.8 million.
  • Its Accumulated Depreciation has fluctuated over the past 5 years, first skyrocketed by 1893.48% in 2021, then surged by 1361.87% in 2022.
  • Over the past 5 years, Ocular Therapeutix's Accumulated Depreciation (Quarter) stood at $15.2 million in 2021, then increased by 13.62% to $17.3 million in 2022, then increased by 17.26% to $20.3 million in 2023, then rose by 16.64% to $23.6 million in 2024, then increased by 16.45% to $27.5 million in 2025.
  • Its last three reported values are $27.5 million in Q4 2025, $23.6 million for Q4 2024, and $20.3 million during Q4 2023.